48 completed, 6 unknown, 4 active not recruiting, 4 recruiting. 67 Phase 2, 4 Phase 1, 4 Phase 3.
Follow Hyperuricemia: new trials by email Literature Review of Hyperuricemia trials Research Report on Hyperuricemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia BR2251, Febuxostat - Gout and Hyperuricemia | Phase 2 | Not yet recruiting | BioRay Pharmaceutical Co., Ltd. | 160 | 2026-04-01 | 2026-03-27 |
| The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia SHR4640 ï¼›Febuxostat, SHR4640 ; Febuxostat, SHR4640 - Primary Gout and Hyperuricemia | Phase 2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 340 | 2026-02-09 | 2026-04-07 |
| A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE) PRX-115, Methotrexate (MTX), PRX-115 placebo - Gout | Phase 2 | Recruiting | Protalix | 150 | 2025-12-22 | 2026-09-29 |
| Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients AR882 75 mg, XOI Low Dose, XOI High Dose - Gout, Gouty Arthritis | Phase 2 | Active not recruiting | Arthrosi Therapeutics | 15 | 2025-12-03 | 2026-05-15 |
| A Dose Escalation Study of IG3018 in Subjects With Hyperuricemia With or Without Chronic Kidney Disease IG3018, Placebo matching IG3018 - Hyperuricemia, Hypouricemia, Renal | Phase 1 / Phase 2 | Recruiting | Intelligem Therapeutics Australia Pty Ltd. | 60 | 2024-11-12 | 2026-02-03 |
| A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects Febuxostat, IBI128 - Gout, Hyperuricemia | Phase 2 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 84 | 2024-07-10 | 2025-03-27 |
| PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function SAP-001 - Gout, Hyperuricemia | Phase 1 / Phase 2 | Active not recruiting | Shanton Pharma Pte. Ltd. | 32 | 2024-04-24 | 2024-12-11 |
| Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia Febuxostat 20MG Tablets, Febuxostat 20MG Placebo, AR882 25MG - Primary Gout, Hyperuricemia | Phase 2 / Phase 3 | Unknown | Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd | 636 | 2024-04-22 | 2024-09-19 |
| Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia dotinurad, dotinurad + allopurinol, allopurinol - Gout, Hyperuricemia | Phase 1 / Phase 2 | Completed | Urica Therapeutics Inc. | 20 | 2023-10-04 | 2026-06-10 |
| Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare Dapansutrile, Placebo Tablet - Acute Gout Flare, Gout Attack | Phase 2 / Phase 3 | Recruiting | Olatec Therapeutics, Inc. | 300 | 2023-01-06 | 2026-03-11 |
| Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001. SAP-001 - Gout | Phase 2 | Active not recruiting | Shanton Pharma Pte. Ltd. | 87 | 2022-12-12 | 2024-11-14 |
| Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients D-0120, Benzbromarone - Hyperuricemia | Phase 2 | Completed | InventisBio Co., Ltd | 121 | 2022-09-28 | 2024-10-15 |
| Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia SHR4640 tablet, febuxostat tablet, SHR4640 placebo tablet - Primary Gout and Hyperuricemia | Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 129 | 2022-09-15 | 2022-08-24 |
| Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease ALLN-346, Placebo - Hyperuricemia, Gout | Phase 2 | Terminated | Allena Pharmaceuticals | 19 | 2022-09-02 | 2023-06-23 |
| Comparative Study Between Febuxostat Versus Vitamin E in Non-alcoholic Steatohepatitis Patients With Hyperuricemia Febuxostat 80 MG Oral Tablet, vit E - Non Alcoholic Steatohepatitis, Hyperuricemia | Phase 2 | Active not recruiting | Tanta University | 70 | 2022-08-25 | 2025-01-23 |
| Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout AR882 Dose 1, AR882 Dose 2, Allopurinol Tablet - Gout, Arthritis, Gouty | Phase 2 | Completed | Arthrosi Therapeutics | 42 | 2022-08-12 | 2025-01-29 |
| Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients AR882 Dose 1, AR882 Dose 2, Placebo - Gout, Arthritis, Gouty | Phase 2 | Completed | Arthrosi Therapeutics | 140 | 2021-11-16 | 2023-05-12 |
| An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201) ALLN-346, Placebo - Hyperuricemia, Gout | Phase 2 | Completed | Allena Pharmaceuticals | 16 | 2021-07-16 | 2023-06-22 |
| A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or Hyperuricemia ABP-671, Placebo - Gout, Hyperuricemia | Phase 2 | Completed | Atom Therapeutics Co., Ltd | 60 | 2020-11-27 | 2023-04-12 |
| Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients Group 1: AR882 Alone and in Combination with Febuxostat (FBX), Group 2: AR882 Alone and in Combination with Allopurinol (ALLO) - Gout Patients | Phase 2 | Completed | Arthrosi Therapeutics | 30 | 2020-02-03 | 2020-11-19 |
Showing 20 of 67. Sign in to see all of them.
Gout (36) · Arthritis, Gouty (6) · Renal Insufficiency, Chronic (4) · Arthritis (3) · Diabetes Mellitus, Type 2 (3) · Leukemia (3) · Lymphoma (3) · Heart Failure (2) · Joint Diseases (2) · Renal Insufficiency (2) · Albuminuria (1) · Arthralgia (1) · Diabetes Complications (1) · Diabetes Mellitus (1)
Pathologic Processes (67) · Pathological Conditions, Signs and Symptoms (67) · Nutritional and Metabolic Diseases (42) · Metabolic Diseases (41) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (37) · Crystal Arthropathies (37) · Genetic Diseases, Inborn (37) · Metabolism, Inborn Errors (37) · Musculoskeletal Diseases (37) · Purine-Pyrimidine Metabolism, Inborn Errors (37) · Rheumatic Diseases (37) · Joint Diseases (35) · Arthritis (34) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8)
Febuxostat (15) · Allopurinol (13) · Colchicine (5) · rasburicase (5) · arhalofenate (4) · dotinurad (4) · ulodesine (4) · Urate Oxidase (3) · ruzinurad (3) · verinurad (3) · Benzbromarone (2) · Prednisone (2) · URC102 (2) · tranilast (2) · Diclofenac (1)
Arthrosi Therapeutics (4) · BioCryst Pharmaceuticals (4) · Gilead Sciences (4) · Jiangsu HengRui Medicine Co., Ltd. (4) · AstraZeneca (3) · Fuji Yakuhin Co., Ltd. (3) · Nuon Therapeutics, Inc. (3) · Sanofi (3) · Allena Pharmaceuticals (2) · Ardea Biosciences, Inc. (2) · Hebei Medical University (2) · InventisBio Co., Ltd (2) · JW Pharmaceutical (2) · Shanton Pharma Pte. Ltd. (2) · Takeda (2)
United States (36) · China (8) · Japan (7) · Taiwan (5) · Australia (3) · Canada (3) · Georgia (3) · France (2) · Germany (2) · Israel (2) · New Zealand (2) · South Korea (2) · Belgium (1) · Bulgaria (1) · Czechia (1)
Alan Hollister, MD, PhD (2) · C Tosone, MS, RAC (2) · R Keenan, MD (2) · Vijay Hingorani, MD, PhD, MBA (2) · A. Ahsan Ejaz, MD (1) · Alexandra Steinberg, MD, PhD (1) · Camila Manrique Acevedo, MD (1) · Carmen Arencibia (1) · Celina Cabale-Scholl, DPT, RN (1) · Cheng Ching Wei, Ph. D. (1) · Chiu-Shong Liu, Director (1) · Christopher Wynne, MBChB, Grad Dip Pharm Med (1) · Chunde Bao (1)
PMID 21849262, PMID 19076979, PMID 22015451, PMID 23006736, PMID 26894653, PMID 27980008, PMID 28975718, PMID 31734820, PMID 31754882, PMID 31792640, PMID 33075806, PMID 33130235, PMID 33693494, PMID 34383954, PMID 37069364, PMID 40383220
R21DK071223 (1)